Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.14% | -0.42% | -73.66% | -38.48% | -43.68% |
| Total Depreciation and Amortization | 84.71% | -9.57% | -17.54% | 1.79% | 0.90% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -66.67% | 0.00% |
| Total Other Non-Cash Items | 14.20% | 33.03% | 28.16% | -52.46% | 35.68% |
| Change in Net Operating Assets | -121.68% | -46.21% | 857.60% | -219.98% | 147.83% |
| Cash from Operations | -9.82% | -33.63% | 9.27% | -99.75% | 10.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.94% | -28.33% | -52.75% | 276.48% | -32.79% |
| Cash from Investing | 101.94% | -28.33% | -52.75% | 276.48% | -32.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 95.30% | -83.92% | 15,546.46% | -5.33% | 45.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 95.30% | -83.92% | 15,546.46% | -5.33% | 45.27% |
| Foreign Exchange rate Adjustments | -100.00% | 77.78% | 250.00% | 50.00% | -1,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.45% | -172.89% | -1.60% | 1,737.83% | -136.04% |